Recent Finacing
Recent Raise
TolerogenixX develops individualized donor-cell–based immunotherapies (MIC-Lx), modifying leukapheresis-derived PBMCs into IV-administered products manufactured within 24 hours to induce donor-specific tolerance in transplantation and autoimmune indications.
